MME and early-onset autosomal dominant Alzheimer disease: For instance, the insulin-degrading enzyme and neprilysin are two metalloproteases that contribute to amyloid β-peptide degradation [43], which therefore represents attractive therapeutic targets for Alzheimer’s disease [44].